AmgenAmgen (NASDAQ: AMGN) reported total revenue increased 3 percent during the fourth quarter of 2011 to $3,973 million versus $3,841 million in the fourth quarter of 2010. For the full year 2011, total revenue increased 4 percent to $15,582 million from $15,053 million in 2010.

Adjusted earnings per share (EPS) were $1.21 for the fourth quarter of 2011, an increase of 3 percent compared to $1.17 for the fourth quarter of 2010. Adjusted net income decreased 6 percent to $1,039 million in the fourth quarter of 2011 compared to $1,103 million in the fourth quarter of 2010.

Full year 2011 adjusted EPS were $5.33 versus $5.21 in 2010, a 2 percent increase. Full year 2011 adjusted net income decreased 3 percent to $4,858 million versus $5,024 million in 2010.

Total product sales increased 4 percent to $3,907 million in the fourth quarter of 2011 versus $3,760 million in the fourth quarter of 2010. U.S. product sales increased 5 percent to $3,007 million in the fourth quarter of 2011 versus $2,869 million in the fourth quarter of 2010. International product sales increased 1 percent to $900 million in the fourth quarter of 2011 versus $891 million in the fourth quarter of 2010. Excluding the $28 million unfavorable impact of foreign exchange in the fourth quarter of 2011, total product sales increased 5 percent and international product sales increased 4 percent. For the year, total product sales increased 4 percent to $15,295 million in 2011 versus $14,660 million in 2010. U.S. product sales increased 4 percent to $11,725 million in 2011 versus $11,254 million in 2010. International product sales increased 5 percent to $3,570 million in 2011 versus $3,406 million in 2010. Excluding the $33 million favorable impact of foreign exchange for the year 2011, total product sales and international product sales both increased 4 percent.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science s promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people s lives.